Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BNT162b2s01 or Comirnaty Booster
NCT04949490Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Jul 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by BioNTech SE. Primary endpoints: Number and Percentage of Participants with Serious Adverse Events or Adverse Events of Special Interest at 26 weeks, Number and Percentage of Participants With Solicited Local Reactions at 7 days and 2 more. Started Jul 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04949490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949490.